摘要
Hormone replacement therapy(HRT)is in use for more than a half of century,but the question of indicationsand ideal candidates for HRT remains unclear.Postmenopausal women are a population with the increasing risksfor cardiovascular diseases which are the main cause of death in this group.Decline in oestrogen
Hormone replacement therapy （HRT） is in use for more than a half of century, but the question of indications and ideal candidates for HRT remains unclear. Postmenopausal women are a population with the increasing risks for cardiovascular diseases which are the main cause of death in this group. Decline in oestrogen concentrations is linked to a number of changes in peri- and postmenopause. These changes are the main components of metabolic syndrome, the epidemic of the modem age. HRT is currently recommended as the gold standard for the management of vasomotor symptoms, but the benefit of HRT on components of metabolic syndrome and risk for cardiovascular events is still uncertain. In the initial reports from the Women＇s Health Initiative trial （WHI）,
